Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

excellent post from RON,


I recently asked a few questions regarding Malcolm's resignation as a director just to clarify the situation for others,as I knew the truth by reading previous announcements on the situation,but obviously getting it across to others was not easy.
This is a mail direct to me about the situation and other comments from Barry J. Muncaster HIMSELF.

RON

Dear Ron.

Thank you for your email regarding BPRG's recent RNS, which was forwarded to
me by BPRG's email system. I no longer use my old BPRG email address because
my consultant agreement completed on April 30th of this year. And before you
ask, no, it was not a reportable event. So please respond to this address if
you feel the need to do so.

Other than being a shareholder and responsible for management of the
litigation with Stanelco (which does not make me an insider) I am no longer
privy to events at BPRG. So any comment I make or opinion I give is entirely
my own.

With regard to the RNS announcing Malcolm's resignation as a director, you
are not alone in having contacted me for my comments. Frankly, I am quite
surprised by the amount of discussion and concern that it caused. It has
been public knowledge for a year that Malcolm had given up his full time
executive role, serving only as a consultant for 3 days a week whilst
retaining his seat on the board by virtue of his quite large shareholding
and because the board needed his vast experience whilst putting together the
technical team required to maximise the commercial benefit of his many
ideas. Friday's announcement was no more and no less than confirmation of
that long held intent.

It would seem that some shareholders are interpreting "immediate effect" to
mean a boardroom bust up or dispute. Nothing could be further from the
truth. I know Malcolm and Graham very well and consider them close and
valued friends. I also know the other board members quite well. There is no
dispute and there has been no bust up. The reason for Malcolm resigning with
immediate effect is quite simple; that's how it's done and that's how it
should be announced. More importantly, Malcolm has helped put in place a
superb technical team who are more than competent to enable the Company to
reach its commercial goals.

In my view, and this view is shared by many in the City, the PLC board
should made up by no more than 4 or 5 high quality and experienced
individuals who together provide the guidance and resources necessary for
the CEO it execute its strategy. We have such a board and it has not been
weakened by Malcolm's resignation. In the last few months we've seen Stephen
Lee appointed as Engineering Director of BTL (BPRG's operating subsidiary)
and Beth Edwards appointed as BTL's Financial Director. In addition, BPRG
has acquired Aquafilm, which is ably run by Scott Schaneville supported by
around 30 staff, of whom most are technically qualified. Ian Thompson
continues to be BTL's Operations Director and Dr. Jason Teckeo heads up film
development whilst Ed Nowak continues essential research into new materials
and applications. Couple all of these skills and competence with those of HH
plus support and initiatives from the engineers and scientists of the
Company's customers and you have a pretty impressive ensemble for such a
small and emerging Company. In short, we have a board that attends to the
needs of the PLC's business with operating subsidiaries that are well
manned, well resourced and most able to deliver on the Company's promises.

Frankly, anyone who thinks BPRG is a one-man business, needs to think again!

I've received many emails complaining about BPRG's apparent lack of quality
PR. Whilst respecting the views of all shareholders - it is their company
after all - I do wish people would stand back for a moment and take in the
full picture. First, let's differentiate between PR (Public Relations) and
IR (Investor Relations). BPRG doesn't need PR. Why? Many reasons, but here's
a couple for starters. First, it doesn't deal with the public, its customers
do and it will be their responsibility to inform and educate end users about
the benefits of XGel at the appropriate time. Does anyone really think for
one minute that major global pharmaceutical companies (who represent BPRG's
customer base) want BPRG out there saying things about XGel before it's
commercially available and in doing so possibly spoiling opportunities in
the market? Second, PR is most often used to attract potential customers to
a company's products and services. In BPRG's case it doesn't need, nor could
it handle any more customers at present; so why spend time, energy and
resources attracting customers who BPRG couldn't satisfy? For goodness sake,
BPRG already has a full compliment of world class customers and in my
opinion it should (and is) concentrate solely on satisfying the needs of its
current customers. Has everyone forgotten the work that's going on with
other yet to be named pharma companies as well as progress with Farmasierra?
I've had comments passed to me about notes written by Scrutable who is
somewhat disappointed that HH will not be exhibiting XGel machines at
conferences. Notwithstanding Scrutable's prior work experience, his views in
this regard show a distinct lack of understanding of BPRG's business model.
BPRG does not want to show its systems to every Tom, Dick or Harry; it
already has its customer base. Why show your technology to all and sundry
and for free? I would understand Scrutable's view if BPRG's offering was a
standard type of production machine, but it isn't. The sale of an XGel
system is a complex process involving licensing of intellectual property,
machine supply, warranty and support, and most importantly film supply. You
don't just place an XGel system on an exhibition booth and wait to see what
or who turns up! BPRG knows who its customers are and is dealing with them;
end of story.

With regard to IR, what would you have the Company do? During its first year
listed on AIM it has provided the market with a good stream of news flow and
some of the announcements have been quite outstanding given that BPRG is a
small UK based company that is pioneering a revolution in a massive and
mature global market. It has kept the market informed of all material
developments and in interviews Graham has explained his vision for the
Company and progress to that end. Announcements may have been worded
differently, but had they been so then I'm sure someone would have found
fault, regardless. Discontent with the wording of statements; delays in
execution of deals; and, delays in the appearance of broker notes is an
understandable reaction, but such should not be of real concern to those
shareholders who have a medium/long term view about the Company's prospects.

Much criticism has been levelled at Collin Stewart. Quit unfairly in my
view. CS has raised funds at 16p, 70p and 110p all within the space of a few
months and in trying market conditions. These funds have enabled the Company
to make massive strides and, most importantly, demonstrate to its major
customers its ability to stay in business and support them when they
introduce new technology to existing global brands as well as to new product
developments. Long term shareholders should value CS' contributions. I have
no doubt that the much talked about broker's note will appear in the not too
distant future.

I agree with general sentiment that the George Tidy affair was an IR foul
up. But, again, what was the Company to do about it? I know for certain that
BPRG has clean hands in the entire affair and that it did the right thing at
the right time. One cannot plan for every eventuality; sometimes things
don't go as planned and this was one such instance. The whole story will
become clear in due course.

I am a close friend of Graham's and I will do as you ask and have a word
with him about the concerns expressed by yourself and others.

Save for my email address, nothing in the email is confidential so please
feel free to disseminate it as you wish.

Sincerely,
Barry J. Muncaster

FMC BioPolymer and Farmasierra Establish Technology Development and Manufacturing Services Agreements for NRobe Dosage Form

FMC BioPolymer (FMC), a business unit of FMC Corporation (NYSE:FMC), has executed agreements with Grupo Farmasierra subsidiaries Farmasierra Manufacturing S.L. and Advanced Technology Pharma S.L. (Farmasierra), whereby Farmasierra will provide FMC with technology development and manufacturing services relating to the commercialisation of NRobe, a new oral dose form system employing pre-formed edible films in a dry, one-step process. Under these agreements, Farmasierra will work closely with FMC to support the development of NRobe technology for pharmaceutical applications. Farmasierra will be FMCs exclusive contract manufacturing partner for NRobe in Europe during the initial commercialization phase.

Robin Mitchell, Business Director responsible for new pharmaceutical technologies at FMC, said: Farmasierra has a reputation for superior quality contract manufacturing services and has assembled a highly qualified team to support its new focus on innovative product development services. By establishing these agreements, FMC expects to accelerate its development plans for NRobe and to be able to offer contract manufacturing services at the earliest possible stage. The enthusiasm of Tom Olleros and his team encourages us that NRobe has great potential and that we will be able to demonstrate significant benefits for pharmaceutical companies and patients through this technology. We have already established excellent working relationships between our companies.

We are delighted to be partnering with FMC in this way commented Dr. Tom Olleros, President of Grupo Farmasierra NRobe is an exciting new technology for making oral dose forms that fits well with Farmasierras desire to focus on innovative yet practical technologies. Quality, service and innovation are the key elements of our strategy for the future. To achieve this, we are partnering with well recognized and reliable companies to supply the pharmaceutical sector with added value technologies.

FMC announced the acquisition of an exclusive worldwide license for the NRobe dosage form, process, equipment and enabling technology from BioProgress (LSE:AIM:BPRG) on February 4, 2004. FMC has assumed full responsibility for the commercialization of NRobe and has a team of technical and commercial staff focused on NRobe development, primarily at its Princeton, New Jersey and Brussels, Belgium laboratories.

- Ends -

For further information:

FMC BioPolymer
Robin Mitchell, Director, New Pharmaceutical Business
Tel: + 1 215 299 5936
robin_mitchell@fmc.com
www.fmcbiopolymer.com

Farmasierra Manufacturing S.L. &
Advanced technology Pharma S.L
Tom Olleros, President
Tel: + 34 916 570 659
tomas@farmasierra.com
www.farmasierra.com



http://www.fmcbiopolymer.com/Biopolymer/V2/BIONewsDetail/0,1418,2674,00.html

A very interesting article by Wendy Durham. Worth a read.

http://www.fillyaboots.com/?mount=Frames/whatwe.html

great link janus. quite frightening as i guess 90% of people have no idea about this going on.

Thanks Janus--this is very interesting and deserves a thread of its own so more of us can learn what is going on!! The Rats!

Cant get link what do you mean by rats? Is something going on behind shareholders backs?

www.fillyaboots.com-as Janus says above. Article on share selling on the Berlin stock exchange driving down prices in AFE, BPRG, PXC, RAB and others. The sellers then disappear and do not deliver stock. I cannot see how they can get away with this? anyone got any info, as it seems they target good companies and wreck our profits!

Seems abit strange to me, it will only be a temporary blip we hope...

have added the berlin page to favourites . will be checking it to see if any other companies i am in get listed there.

Has this got something to do with LSE selling out to an EU exchange?

I have been unable to get the link too Adie today though I got it yesterday. How is it possible to sell stock you don't own other than by spreadbetting? I'm prepared to take a risk under the conditions I thought the market operated but this puts me off dealing completely. Thankfully it's June and I sold up mostly and perhaps it will all be sorted out by St Swithin's day (not sure if that's the right saint)
I did notice that there are a lot of action sites in the USA and Canada. Anyone heard of one in the UK?

If you have access to Ample a poster there makes a few valid points (wowbagger). Am still in from last year (did not take profits) and will hold as believe this company has lots of potential, looking forward to brokers note whenever that may appear. Good luck to all holders.

news on BPRG SITE-don't know how to get it on here.

ep

Here it is:-

03 June 2004
Update on FMC BioPolymer Global Licensing Agreement
In February 2004, BioProgress plc (BioProgress) announced an agreement with FMC BioPolymer (FMC), a business unit of FMC Corporation (NYSE:FMC) whereby FMC acquired an exclusive worldwide licence for the BioProgress NROBE dosage form, process, equipment and enabling technology. FMC has subsequently assumed full responsibility for the commercialisation of NROBE and has a team of technical and commercial staff focused on NROBE development, primarily at its Princeton, New Jersey and Brussels, Belgium laboratories.

The licensing agreement runs to 2023 and FMC has provided contractual assurances that a minimum number of NROBE machines will be purchased from BioProgress within the first six years following commercialisation. It is the continued expectation of BioProgress that the contracts are likely to generate a minimum of US$160 million of revenue to BioProgress over the first six years following commercialisation, including machine sales, film manufacturing contract sales and royalties payable to BioProgress on the revenues generated by FMC from sales of film, whether produced or developed by BioProgress or by FMC, for use with the NROBE dosage form.

As part of the drive towards commercialisation, FMC has now executed agreements with subsidiaries of Grupo Farmasierra (Farmasierra), whereby Farmasierra will provide FMC with technology development and manufacturing services relating to the commercialisation of NROBE. Under these agreements, Farmasierra will work closely with FMC to support the development of NROBE technology for pharmaceutical applications. Farmasierra will be FMCs exclusive contract manufacturing partner for NROBE in Europe during the initial commercialization phase. By establishing these agreements, FMC expects to accelerate its development plans for NROBE and to be able to offer contract manufacturing services at the earliest possible stage.

Graham Hind, Chief Executive of BioProgress, said: These agreements between FMC BioPolymer and Farmasierra bring together a global pharmaceutical supplier and a company with a reputation for superior quality contract manufacturing services. I also believe they validate our confidence in NROBE and its potential for capturing a significant share of the sizeable market for capsules and tablets over the long-term. Finally, it means that the commercialisation of NROBE is likely to be accelerated, which has positive implications for the start of revenue flows for BioProgress.

JOEHARGAN1-THANKS

Exclusive licensing option agreement with Wyeth for XGEL(R) SWALLOW liquid fill capsule technology


Looking good

http://www.uk-wire.com/cgi-bin/articles/200406070700044490z.html

BioProgress PLC
07 June 2004


Press Release 7 June 2004


BioProgress plc

('BioProgress' or 'the Company')


Exclusive licensing option agreement with Wyeth
for XGEL(R) SWALLOW liquid fill capsule technology


BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, announces today it has executed an exclusive
option agreement with Wyeth to complete due diligence and enter into
negotiations to license its XGEL(R) SWALLOW liquid fill capsule technology for
certain specified product fields.

The option agreement provides for an upfront payment of a six figure sum on
execution providing Wyeth with an exclusive opportunity to evaluate the
technology and negotiate terms of a technology licensing agreement, machine
supply agreement and the film supply agreement within the fields. Francis
Sullivan, spokesperson for Wyeth Consumer Healthcare, said: 'We believe
BioProgress has developed some interesting technology. We are entering into
this agreement to secure an exclusive position to enable a full detailed
evaluation of the opportunity.'

It is intended that BioProgress through Harro Hoefliger will provide liquid fill
XGEL(R) machines and BioProgress will supply film for the machines from its
newly acquired film production facility in Tampa, Florida USA, and from its UK
film production facility when that comes on-line. BioProgress will also receive
a licence fee within any exclusively licensed product field which uses the
liquid dosage form.

Graham Hind, Chief Executive Officer of BioProgress plc, said: 'This is a
significant agreement for BioProgress as it involves another of our new dosage
form technologies with a major US pharmaceutical customer.

'XGEL(R) SWALLOW liquid fill capsule technology has unique properties which
makes it a very attractive delivery platform for pharmaceutical manufacturers.
We believe this technology has the potential to be the preferred alternative to
current liquid fill systems'.

New OTC deal in the frame for BioProgress?

- 08/06/2004 - UK encapsulation specialist BioProgress has signed a license option deal for a liquid fill technology with the consumer healthcare division of US drug major Wyeth. If taken to fruition, the agreement would mark the companys second partnership in the over-the-counter (OTC) drug sector.

Wyeth is evaluating BioProgress XGEL SWALLOW liquid fill capsule technology for certain specified product fields. The SWALLOW system makes use of a single, compact machine is claimed to improve on the lengthy, multi-step manufacturing process required for gelatin soft capsules. Wyeth is thought to be the first commercial partner for this technology.
In March, BioProgress signed an agreement for its TABWRAP tablet coating technology with an unnamed company that will use it for OTC applications. Both SWALLOW and TABWRAP are based on BioProgress' animal-free cellulose film technology.

The option agreement provides for an upfront payment of an unspecified six-figure sum on execution. Wyeth will evaluate the technology and, if its deliberations are positive, can negotiate terms of a technology license and machine/film supply agreement.

It is intended that BioProgress - through its machinery partner Harro Hoefliger - will provide liquid fill XGEL machines and BioProgress will supply film for the machines from its newly acquired film production facility in Florida, US, and from its UK film production facility when that comes on-line.

Graham Hind, BioProgress chief executive, said that the company is positioning SWALLOW as a preferred alternative to current liquid fill systems, helped by the fact that its use of a single, compact machine is an improvement over the lengthy, multistep manufacturing process required for gelatin.

With most of the capital-intensive infrastructure eliminated, SWALLOW makes it easier for companies to adopt in-house production. And as capacity requirements increase, more self-contained systems can simply be added, claims the UK company.

SWALLOW capsules can be produced in a variety of shapes, sizes, colours and thickness, and can be modified to meet specific customer and product requirements for dissolution
http://www.inpharma.com/news/news-NG.asp?id=52654

BioProgress plc

('BioProgress' or 'the Company')

NASDAQ listing


BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, announces that the board of directors of the
Company has decided to apply to list American Depository Receipts (or ADRs)
representing Ordinary Shares of the Company on the NASDAQ National Market.

The dual NASDAQ listing will create a more efficient trading platform for the
significant number of US-based Shareholders that BioProgress already has, as
well as any new US shareholders. Since the Company is already required to file
reports with the US Securities and Exchange Commission, the additional costs and
regulatory hurdles involved in a dual listing on the NASDAQ National Market will
be relatively small.

Since BioProgress Technology International Inc. delisted from the NASD OTC
Bulletin Board in May 2003, the Company now has a significant part of its
business in the USA. This includes important agreements signed with US-based
pharmaceutical companies as well as the acquisition of certain assets of the
Aquafilm business in Florida.

BioProgress is currently looking to appoint US advisers to assist in this
process and will provide further information at an appropriate stage.


Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. This announcement contains certain 'forward-looking
statements' within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking statements.
The forward-looking statements in this release include statements addressing
future financial and operating results and the timing and benefits of the
reorganisation. Detailed information about factors pertinent to the business of
the company that could cause actual results to differ is set forth in the
Company's filings with the Securities and Exchange Commission. The Company is
under no obligation to (and expressly disclaim any such obligation to) update or
alter its forward-looking statements whether as a result of new information,
future events or otherwise.

- Ends -


For further information:
BioProgress plc
Graham Hind, Chief Executive Tel: +44 (0) 1354 655 674
grahamhind@bioprogress.com www.bioprogress.com

What's going on ?